Meeting
2020 ASCO Virtual Scientific Program
Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).
Authors
Minetta C. Liu
Mayo Clinic, Rochester, MN
Minetta C. Liu , David W. Hillman , Ashley Elizabeth Frith , Alan P. Lyss , Douglas Jay Weckstein , Alvaro Moreno-Aspitia , Nguyet Le-Lindqwister , Claudine Isaacs , Donald B. Wender , DeQuincy Andrew Lewis , John T. Cole , Anthony John Jaslowski , Kendrith M. Rowland , Thomas H. Openshaw , Bret Edward Buckley Friday , Gini F. Fleming , Erik Asmus , Lauren J. Rogak , Ethan M. Basch , Amylou C. Dueck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT02037529
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1016)
DOI
10.1200/JCO.2020.38.15_suppl.1016
Abstract #
1016
Poster Bd #
101
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.
First Author: Joyce O'Shaughnessy
Poster
2018 ASCO Annual Meeting
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).
First Author: Joyce O'Shaughnessy
Poster
2013 ASCO Annual Meeting
A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.
First Author: Peter Andrew Kaufman
Poster
2013 ASCO Annual Meeting
Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.
First Author: Javier Cortes